BLOOD ADV
| WoS 期刊 JCR 分区 (2026 · JIF) | 综合 SCIE | Q1 | ||
|---|---|---|---|---|
| 学科 | 收录集 | JIF 分区 | JIF 排名 | JIF 百分位 |
| 血液学 Hematology | SCIE | Q1 | 13/103 |
87.4%
|
| 学科 | 收录集 | JCI 分区 | JCI 排名 | JCI 百分位 |
|---|---|---|---|---|
| 血液学 Hematology | SCIE | Q1 | 11/87 JCI 1.74 |
88.5%
|
Blood Advances is a prestigious, peer-reviewed, open-access medical journal published by the American Society of Hematology (ASH). With an ISSN of 2473-9529 and an abbreviation of BLOOD ADV, the journal serves as a vital complement to its flagship title, *Blood*, by focusing on the rapid dissemination of high-quality original research in hematology. Its scope encompasses the full spectrum of benign and malignant hematologic disorders, including hemostasis and thrombosis, red cell biology, hematologic malignancies, transfusion medicine, stem cell transplantation, and gene therapy. The journal publishes original Articles, Review Articles, and Brief Reports, with a strong emphasis on translational and clinical research that directly advances patient care. The target audience includes hematologists, oncologists, basic scientists, clinical researchers, and allied health professionals dedicated to blood disorders. A defining feature is its open-access model, ensuring that all content is freely and immediately available to the global scientific community, thereby maximizing the reach and impact of published findings. As of 2026, *Blood Advances* holds an impressive Journal Citation Reports (JCR) Impact Factor of 7.700 and is ranked in the Q1 quartile, placing it among the top-tier journals in the field of hematology. This standing, combined with its rigorous peer review and association with ASH, establishes the journal as an authoritative and highly influential platform for the most current and significant advances in blood science and clinical practice.